On the stock market since 1999, it operates in the world of health and science. It has 31 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $2.3M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 10 buys and 1 sell. Management buying with its own money is usually read as a good sign.
It pays out $7.35 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 21% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, FZMD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: FZMD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.